<DOC>
	<DOCNO>NCT01699737</DOCNO>
	<brief_summary>The purpose study evaluate effect JTT-851 diabetes well assess safety , tolerability , pharmacokinetics JTT-851 type 2 diabetic patient either treated metformin treatment-naïve .</brief_summary>
	<brief_title>Safety Efficacy Study JTT-851 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , placebo active-controlled ( glimepiride ) , multi-center , parallel-group study investigate effect JTT-851 HbA1c ancillary efficacy parameter assess safety , tolerability , pharmacokinetics JTT-851 inadequately-controlled treatment-naïve metformin-treated type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Males female type 2 diabetes , 1870 year age Visit 1 Managing diabetes diet exercise currently treat stable dose metformin ( least 1500 mg/day ) Glycosylated hemoglobin Visit 1 7.5 % 10.0 % , metformin 7.5 % 10.9 % , without treatment Body mass index ( BMI ) ≥ 23.0 kg/m^2 ≤ 45.0 kg/m^2 Visit 1 Females pregnant breastfeed Known medical history presence type 1 diabetes acute metabolic diabetic complication , unstable rapidly progress retinopathy , nephropathy neuropathy Acute coronary syndrome uncontrolled hypertension Does meet diet previous/concomitant medication restriction criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Diabetes</keyword>
</DOC>